Compare FRBT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRBT | DSGN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.0M | 853.8M |
| IPO Year | 2026 | 2021 |
| Metric | FRBT | DSGN |
|---|---|---|
| Price | $18.58 | $12.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 63.0K | ★ 666.4K |
| Earning Date | N/A | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.72 | $5.28 |
| 52 Week High | $22.00 | $17.25 |
| Indicator | FRBT | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 28.56 |
| Support Level | $18.24 | $11.65 |
| Resistance Level | $19.44 | $13.54 |
| Average True Range (ATR) | 0.67 | 0.70 |
| MACD | 0.03 | -0.35 |
| Stochastic Oscillator | 47.11 | 3.52 |
Forbright Inc is a bank holding company. Along with its subsidiaries, it operates as a state chartered non-member bank, which serves the needs of individuals, small and medium sized businesses, and professional concerns. Its services include deposit and retail banking through a digital deposit platform, as well as financing and lending products such as lender finance loans, fund finance loans, healthcare finance loans, real estate loans, working capital facilities, warehouse lines of credit, and term loans.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.